ArticleDiscover oncology2026
A network toxicology and molecular docking study predicting putative molecular targets and pathways linking bisphenol a exposure to diffuse large B-cell lymphoma.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisphenol A (BPA) is a pervasive environmental endocrine disruptor implicated in hormone-related cancers.However, its association with non-hormone-dependent malignancies such as Diffuse Large B-cell Lymphoma (DLBCL) remains poorly understood.This study aimed to predict the potential molecular mechanisms linking BPA exposure to DLBCL pathogenesis through an integrated approach combining network toxicology and molecular docking.We systematically identified 46 overlapping genes shared between BPA-associated targets and DLBCL-related genes. Protein-protein interaction network analysis indicate six hub genes(HSP90AB1, HSPA8, CCNA2, CDK1, LDHA, and HSPA14),with HSP90AB1 exhibiting the highest topological centrality.Functional enrichment analysis demonstrated that these genes are significantly enriched in key oncogenic signaling pathways, including the PI3K-Akt and MAPK pathways, as well as critical biological processes such as protein folding and cell cycle regulation. Molecular docking simulations further predicted the stable binding affinity between BPA and each of the six hub proteins, with binding energies below - 6.0 kcal/mol. Collectively, our computational findings suggest a putative mechanistic framework in which BPA may contribute to DLBCL development by directly interacting with and potentially dysregulating central regulatory nodes in cellular networks, particularly the molecular chaperone HSP90AB1. These predictions require experimental validation but provide a basis for future mechanistic studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.